NCT02189837View on ClinicalTrials.gov

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

PHASE3CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

July 8, 2014

Primary Completion Date

February 13, 2015

Study Completion Date

March 5, 2015

Conditions
Primary Hyperlipidemia and Mixed Dyslipidemia
Interventions
BIOLOGICAL

Evolocumab

Administered by subcutaneous injection

DRUG

Atorvastatin

Administered by mouth

DRUG

Placebo to Evolocumab

Administered by subcutaneous injection

DRUG

Placebo to Atorvastatin

Administered by mouth

Trial Locations (2)

5000

Research Site, Adelaide

6009

Research Site, Nedlands

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02189837 - Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody | Biotech Hunter | Biotech Hunter